英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
reedition查看　reedition　在百度字典中的解释百度英翻中〔查看〕
reedition查看　reedition　在Google字典中的解释Google英翻中〔查看〕
reedition查看　reedition　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Official Caregiver Site for YUVIWEL | YUVIWEL® (navepegritide)
    Learn more about this FDA-approved treatment for children with achondroplasia See full Prescribing and Safety information
  • FDA Approves Once-Weekly YUVIWEL® (navepegritide) for . . .
    “The approval of once-weekly YUVIWEL is a major step forward in the treatment of children with achondroplasia, giving physicians for the first time the option of prescribing a once-weekly medicine backed by compelling efficacy and excellent tolerability data from three randomized, double-blind, placebo-controlled clinical trials,” said Carlos A Bacino, MD, FACMG, Professor of Molecular
  • Approval Label_219164Orig1s000lbl
    YUVIWEL is a C-type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses (1) This indication is approved under accelerated approval based on an improvement in annualized growth velocity Continued approval for this indication may be contingent upon verification and description of clinical
  • Yuviwel: Uses, Dosage, Side Effects, Warnings - Drugs. com
    Yuviwel is used to increase linear growth in children 2 years and older with achondroplasia with open epiphyses It is given once-weekly by subcutaneous injection Learn about side effects, the mechanism of action, and administration
  • Navepegritide (Yuviwel®) for Children with Achondroplasia . . .
    Navepegritide (Yuviwel®) for Children with Achondroplasia: New Drugs and Therapeutics Written by Anna Ryabets-Lienhard, DO Edited by Neha Patel, DO and Emily Breidbart, MD On February 27th, 2026, the FDA approved Navepegritide (Yuviwel®), a C-natriuretic peptide (CNP) analog prodrug developed by Ascendis Pharmaceuticals using TransCon® CNP technology 1 The once‑weekly subcutaneous therapy
  • Achondroplasia Treatment: New 2026 FDA Approval | Medaptly
    Achondroplasia treatment Yuviwel (navepegritide) is the first once-weekly FDA-approved option for children ages 2 and older, with phase 2b trial growth data
  • FDA approves Ascendis achondroplasia treatment Yuviwe
    The FDA has approved Ascendis' Yuviwel, a once-weekly injection to treat children with achondroplasia, a rare genetic disorder which causes dwarfism
  • Yuviwel for Achondroplasia - WebMD
    Yuviwel increased growth rate across ages and genders However, the treatment difference between Yuviwel and placebo was larger in children aged 5 years or older than in those younger than 5 years
  • Once-Weekly Treatment Approved for Achondroplasia in Kids
    The FDA approved navepegritide (Yuviwel) for children ages 2 and older with achondroplasia, the most common form of dwarfism, developer Ascendis Pharma announced on Friday The prodrug of C-type
  • FDA Approves Yuviwel for Weekly Treatment of Achondroplasia
    The recent authorization of Yuviwel by the FDA represents a transformative moment for thousands of families navigating the complexities of achondroplasia, effectively dismantling a long-standing market monopoly For the first time,





中文字典-英文字典  2005-2009